AZTAHealthcare · Medical Instruments & SuppliesAZTA Stock Forecast: Azenta, Inc. Price Predictions for 2026-2027
The 6 Wall Street analysts covering Azenta, Inc. hold a median 12-month price target of $37 — -5.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 26 Oct 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.
AZTA stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Azenta, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (89): Reported profit is backed by cash, and the company is not expanding recklessly.
Revisions (43): Analysts have, on balance, been cutting their forecasts.
Size (37): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
AZTA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AZTA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits −5.3% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Sept 2026 | Needham | Reiterates | Buy | $37 |
| 6 Aug 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 6 Aug 2026 | Evercore ISI Group | Maintains | Outperform | $28 → $35 |
| 5 Aug 2026 | Needham | Maintains | Buy | — |
| 5 Aug 2026 | Needham | Maintains | Buy | $33 → $37 |
| 6 May 2026 | Needham | Maintains | Buy | $44 → $33 |
| 6 May 2026 | Needham | Maintains | Buy | — |
| 6 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 17 Mar 2026 | Needham | Reiterates | Buy | — |
| 5 Feb 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 4 Feb 2026 | Jefferies | Maintains | Buy | — |
| 4 Feb 2026 | Needham | Reiterates | Buy | — |
| 8 Jan 2026 | TD Cowen | Maintains | Hold | — |
| 5 Jan 2026 | Evercore ISI Group | Upgrade | Outperform | — |
| 19 Dec 2025 | Needham | Maintains | Buy | — |
| 25 Nov 2025 | Raymond James | Maintains | Outperform | — |
| 21 Nov 2025 | Needham | Maintains | Buy | — |
| 30 Oct 2025 | Jefferies | Upgrade | Buy | — |
| 6 Aug 2025 | Raymond James | Upgrade | Outperform | — |
| 5 Aug 2025 | Evercore ISI Group | Maintains | In-Line | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
AZTA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
AZTA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, Azenta, Inc. returned +22.6% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
AZTA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Azenta, Inc. (AZTA) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 31.7×
- Price / sales
- 2.6×
- Price / book
- 1.1×
- EV / EBITDA
- 40.2×
Cheaper than 24% of US stocks
Cheaper than 44% of US stocks
Cheaper than 68% of US stocks
Cheaper than 6% of US stocks
- Revenue growth (YoY)
- 12.0%
- Earnings growth (YoY)
- 12.0%
- Gross margin
- 44.9%
- Operating margin
- −2.3%
- Net margin
- −20.0%
Higher than 58% of US stocks
Higher than 51% of US stocks
Higher than 56% of US stocks
Higher than 30% of US stocks
Higher than 16% of US stocks
- Return on equity
- −7.0%
- Return on assets
- −0.7%
- Dividend yield
- 1.1%
Higher than 38% of US stocks
Higher than 41% of US stocks
Higher than 71% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Azenta, Inc. (AZTA) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Azenta, Inc. has a market value of $1.6B and an enterprise value of $1.3B.
Revenue in the twelve months to 30 June 2026: $613.6M. The latest quarter grew 12.0% year on year.
Net income over the same four quarters: −$122.9M, a −20.0% net margin.
Diluted earnings per share, trailing twelve months: $−2.76.
Free cash flow in the twelve months to 30 June 2026: $9.9M.
Trailing P/E: 31.7×; forward P/E: 70.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.08%, paying out 0% of earnings.
Azenta, Inc. employs 2,900 people — $212K of revenue per employee.
Data provided by Twelve Data
AZTA vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Azenta, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about AZTA stock
What is the AZTA stock price forecast for 2026-2027?
The 6 Wall Street analysts covering Azenta, Inc. have a median 12-month price target of $37, with estimates ranging from $33 to $44. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is AZTA stock a buy right now?
Of the 6 analysts covering Azenta, Inc., 3 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Azenta, Inc. 81 out of 100 across roughly 4,600 US stocks as at 26 Oct 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank AZTA?
As at 26 Oct 2026, Azenta, Inc. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (89 of 100).
Will AZTA stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts implies -5.3% from the last close, and Ticker Nerd's factor model ranks Azenta, Inc. 81 out of 100 as at 26 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the AZTA stock forecast for 2030?
No analyst covering Azenta, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AZTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $33 to $44 over the next 12 months.
How has AZTA stock performed over the past year?
Azenta, Inc. returned +22.6% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Azenta, Inc. do?
Azenta, Inc. is a life sciences tools and services company focused on sample management, biostorage, and genomic services.
About Azenta, Inc.
Azenta, Inc. is a life sciences tools and services company focused on sample management, biostorage, and genomic services. The company provides automated storage systems, temperature-controlled logistics, laboratory consumables, informatics, and repository services that help customers preserve, track, and manage biological and chemical samples across research, clinical development, and commercialization workflows. Azenta also offers sequencing, gene synthesis, and related multiomics services for pharmaceutical, biotechnology, academic, and healthcare customers. Its solutions are used to support drug development, clinical research, advanced therapies, and biospecimen handling, making the company an important provider of infrastructure for sample integrity and data-driven life sciences operations. Azenta is headquartered in Burlington, Massachusetts, and serves a global customer base across North America, Europe, and Asia.
CEO Dr. Martin D. Madaus D.V.M., Ph.D. · 2,900 employees · United States · https://www.azenta.com